of HUMALOG Insulin in Patient With COVID-19
is an infectious respiratory disease caused by SARS-CoV-2, previously
referred to as "2019 novel coronavirus."1
has not studied the use of Humalog Insulin in patients with COVID-19
nor in patients at risk of contracting COVID-19.
Humalog insulin label doesn't state any specific recommendations.
However, it does state that insulin requirements may be increased
during illness or emotional disturbances.2
requirements may be increased by substances with hyperglycaemic
activity, such as corticosteroids. Insulin requirements may be
reduced in the presence of substances with hypoglycaemic activity,
such as salicylates (for example, acetylsalicylic acid).2
should use their clinical judgment in determining the most
appropriate approach in treating a patient with Humalog insulin who
has confirmed or suspected COVID-19.
Disease Resources for COVID-19
current information on COVID-19, please refer to
Naming the coronavirus disease (COVID-19) and the virus that causes
it. World Health Organization. Accessed March 17, 2020.
Humalog [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
Coronavirus disease (COVID-19) outbreak. European web page of the
World Health Organization. Accessed March 20, 2020.
International Diabetes Federation Europe. COVID-19 outbreak:
guidance for people with diabetes.
Accessed March 18, 2020
COVID-19. European Centre for Disease Prevention and Control.
Accessed March 20, 2020.
= coronavirus disease 2019
= European Centre for Disease Prevention and Control
WHO = World Health Organization (European regional office)
= International Diabetes Federation
= Eli Lilly and Company
= severe acute respiratory syndrome coronavirus 2